Welcome to our dedicated page for Dynavax Technolo SEC filings (Ticker: DVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dynavax Technologies Corporation (DVAX) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as a Nasdaq Global Select Market issuer. Dynavax uses these filings to report financial results, clinical milestones and significant corporate events related to its vaccines business, including HEPLISAV-B®, CpG 1018® adjuvant and its pipeline of adjuvanted vaccine candidates.
Among the most frequently referenced documents are Form 8-K current reports. Dynavax files 8-Ks to furnish quarterly financial results, such as the second and third quarter 2025 earnings releases, under Item 2.02 (Results of Operations and Financial Condition). These filings typically attach press releases that detail HEPLISAV-B net product revenue, total revenues, research and development spending, selling, general and administrative expenses, and adjusted EBITDA, along with management commentary and updated guidance.
Dynavax also uses Form 8-K to disclose clinical and pipeline developments and corporate governance changes. For example, an August 21, 2025 8-K furnished a press release and corporate presentation on topline Phase 1/2 results for Z-1018, the company’s shingles vaccine candidate. Another 8-K dated October 15, 2025 described changes in senior management roles, including transitions in the positions of President, Chief Operating Officer and Chief Medical Officer.
In addition, Dynavax’s filings include information on its capital markets activities, such as share repurchase programs and other financial measures, and will incorporate documents related to significant transactions. The announced agreement for Sanofi to acquire Dynavax through a cash tender offer and subsequent merger is expected to generate tender offer materials on Schedule TO and a Solicitation/Recommendation Statement on Schedule 14D-9, as described in the companies’ joint press release.
On Stock Titan, users can review Dynavax’s SEC filings as they are made available from EDGAR and access AI-powered summaries that explain the key points of lengthy documents like earnings releases and transaction-related filings. This includes highlighting items such as quarterly performance trends, updates on vaccine programs like HEPLISAV-B and Z-1018, and the implications of corporate events. The page also surfaces filings related to executive changes and other material events so that investors can quickly understand what Dynavax has reported to regulators.
Dynavax Technologies Corp. had a major shareholder tender all of its shares as part of a merger with Sanofi. Deep Track Biotechnology Master Fund, Ltd., a 10% owner, disposed of 15,726,349 shares of common stock on February 10, 2026 through a tender-offer transaction at $15.50 per share in cash. This occurred at the effective time of a merger in which a Sanofi subsidiary combined with Dynavax, leaving Dynavax as an indirect wholly owned subsidiary of Sanofi. Following the transaction, the reporting holders no longer owned Dynavax common stock from this position.
Dynavax Technologies Corporation (DVAX) received an amended Schedule 13G/A from Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin reporting that they now beneficially own 0 shares of Dynavax common stock, representing 0% of the outstanding shares.
The filing confirms they have no sole or shared power to vote or dispose of Dynavax stock. It is characterized as a passive filing, stating the securities were not acquired or held to change or influence control of Dynavax. The ownership percentages are based on 117,424,968 shares outstanding as referenced from Dynavax’s 10-Q filed on November 5, 2025.
Dynavax Technologies CEO Ryan Spencer reported multiple equity transactions tied to the company’s acquisition by SANOFI. A SANOFI subsidiary completed a tender offer to buy all Dynavax common shares for $15.50 per share in cash, then merged into Dynavax on February 10, 2026, leaving Dynavax as an indirect wholly owned subsidiary.
At the merger’s effective time, each Dynavax common share Spencer held was exchanged for the $15.50 cash offer price. All of his outstanding stock options, restricted stock units (RSUs), and performance stock units (PSUs) were cancelled and converted into cash rights based on the offer price. PSU payouts were calculated assuming 150% of target performance, and portions of equity awards granted in 2025 remain subject to vesting, with 50% of related cash amounts scheduled to vest six months after the effective time.
Dynavax Technologies senior vice president and general counsel John L. Slebir filed a Form 4 detailing how his equity was treated in the company’s merger with Sanofi. Sanofi’s tender offer acquired all Dynavax common stock for $15.50 per share, with the merger becoming effective on February 10, 2026.
At the effective time, each share of Dynavax common stock held by Slebir was tendered for the cash offer price. All outstanding stock options, restricted stock units (RSUs), and performance stock units (PSUs) were cancelled and converted into rights to receive cash based on the offer price and award terms.
For PSUs and RSUs, the cash amount is generally calculated using the number of shares underlying the awards multiplied by the $15.50 offer price, with PSU performance deemed at 150% of target. For equity awards granted in 2025, half of the resulting cash is subject to continued vesting and is scheduled to vest six months after the merger’s effective time.
Dynavax Technologies VP and Chief Accounting Officer Joseph Metzinger reported automatic changes to his equity following the company’s merger with Sanofi. A Sanofi subsidiary acquired all Dynavax common shares for
At the merger’s effective time, Metzinger’s 7,129 shares of common stock were tendered for the
Dynavax Technologies’ SVP and CFO Kelly MacDonald reported equity transactions tied to the company’s acquisition by Sanofi. Sanofi’s subsidiary completed a tender offer for all Dynavax common shares at $15.50 per share in cash and then merged into Dynavax on February 10, 2026.
At the merger’s effective time, MacDonald’s 60,204 shares of common stock were exchanged for the cash offer price. Performance stock units of 46,430 from a 2024 grant and 42,424 from a 2025 grant, multiple stock options covering amounts such as 350,000 and 90,500 shares, and restricted stock units of 15,476 and 28,283 shares were all cancelled and converted into cash based on the offer price, with portions of certain 2025 awards remaining subject to vesting six months after the merger.
Dynavax Technologies director Emilio Emini reported the cash-out of his equity awards in connection with the company’s merger with Sanofi. On February 10, 2026, Sanofi’s subsidiary completed a tender offer and merged with Dynavax, paying
At the merger’s effective time, Emini’s 10,075 restricted stock units were cancelled and converted into the right to receive cash based on the number of underlying shares multiplied by
Dynavax Technologies director Myers Scott Dunseth reported the cash-out of his equity in connection with Dynavax’s merger with Sanofi. Under the Merger Agreement, Sanofi’s subsidiary acquired all Dynavax common shares for $15.50 per share in cash via a tender offer, followed by a merger completed on February 10, 2026.
At the merger’s effective time, each share of Dynavax common stock held by the director was tendered for the $15.50 cash offer price. All restricted stock units he held, whether vested or unvested, were cancelled and converted into the right to receive cash equal to the number of underlying shares multiplied by the $15.50 offer price. Each of his outstanding stock options first became fully vested and was then cancelled, with a cash right equal to the number of option shares multiplied by the excess of the $15.50 offer price over the option’s exercise price.